6,215 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,215 shares of the company’s stock, valued at approximately $389,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. CWM LLC raised its position in shares of CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares during the period. Tradewinds Capital Management LLC raised its position in shares of CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after purchasing an additional 600 shares during the period. Blue Trust Inc. bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $32,000. Headlands Technologies LLC bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $34,000. Finally, Bourgeon Capital Management LLC raised its position in shares of CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Down 1.3 %

Shares of NASDAQ CRSP opened at $57.96 on Wednesday. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The firm’s 50-day simple moving average is $73.89 and its 200 day simple moving average is $63.30.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. The firm’s quarterly revenue was up 3253.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.41) EPS. Research analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.48, for a total value of $1,449,600.00. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $15,084,682.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $72.48, for a total transaction of $1,449,600.00. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $15,084,682.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,410 shares of company stock valued at $7,984,677. Company insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CRSP shares. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, April 11th. Mizuho boosted their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Finally, Morgan Stanley boosted their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $74.93.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.